A phase II study of hydroxyurea combined with gemcitabine in patients with head and neck squamous carcinoma and gene expression profiles correlated to poor response.

Conclusions The combination of HU and gemcitabine may be useful in HNSCC control with reasonable tolerance and toxicity. Based on gene expression profiles, a subset of patients may be potentially identified to gain increased treatment benefits.
Source: Head and Neck Oncology - Category: Cancer & Oncology Source Type: research